Oxalóza u nemocných v pravidelném dialyzacním lécení
[Oxalosis in patients on regular dialysis therapy]
Language Czech Country Czech Republic Media print
Document type Case Reports, English Abstract, Journal Article
PubMed
1413575
- MeSH
- Renal Dialysis adverse effects MeSH
- Cardiomyopathies etiology metabolism MeSH
- Skin Diseases etiology metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Bone Diseases etiology metabolism MeSH
- Calcium Oxalate metabolism MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Calcium Oxalate MeSH
The authors draw attention to the case of a 46-year-old man who developed after three years of regular dialyzation treatment three times a week the first manifestations of acquired generalized oxalosis. The oxalosis was most marked on the skin, skeleton, heart, and kidneys. Oxalosis was confirmed after eight years of dialysis after death by post-mortem and histological examination and microscopic detection of oxalate crystals. The authors recommend that as part of regular dialyzation treatment patients should not be given more than 100 mg ascorbic acid per day. Oxalates are also the end product of degradation of ascorbic acid and high doses may lead also to hyperoxalosis. Moreover deposits in some visceral organs, in particular the heart may cause clinical manifestations. In the authors patients they caused attacks of auricular flutter. Although these clinical manifestations develop only rarely, the latent form of acquired oxalosis is probably more frequent.